BioAtla (BCAB) Gains from Sales and Divestitures (2022 - 2023)
BioAtla's Gains from Sales and Divestitures came in at -$185,000 for FY2025.
Analysis
BioAtla (BCAB) Gains from Sales and Divestitures (2022 - 2023) Analysis & Trends
Going back to FY2019, BioAtla's Gains from Sales and Divestitures data covers 5 years.
- The FY2025 figure represents the lowest annual Gains from Sales and Divestitures in data going back to FY2019.
- Per Business Quant, earlier years put Gains from Sales and Divestitures at -$2,000 in FY2023, -$13,000 in FY2022 and -$4,000 in FY2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn |
| 10 | BioAtla | 2.74 Mn | 2.74 Mn | - |
API Access
BioAtla Gains from Sales and Divestitures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=BCAB&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "gains-from-sales-and-divestitures", "ticker": "BCAB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=BCAB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();